-
Neuralstem Expands Lou Gehrig’s Disease Trials
Rockville, Maryland-based Neuralstem’s NSI-566/ALS Phase II trial’s approval by the FDA was reported in the D.C. region business journal.
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.